No Priors: Artificial Intelligence | Technology | Startups
No Priors: Artificial Intelligence | Technology | Startups
Conviction
How AI Will Accelerate Breakthroughs in Biotechnology with Benchling CEO Sajith Wickramasekara
48 minutes Posted Nov 13, 2025 at 11:00 am.
– Sajith Wickramasekara Introduction
– Origin and Mission of Benchling
– The Drug Development Process
– Current State of the Biotech industry
– AI’s Role in Biotech
– Benchling AI and Its Impact
– The Future of AI in Biotech
– Debunking AI Drug Discovery Myths
– Data’s Role in Biotech
– The Importance of Tools in Pharma
– AI’s Impact on Scientific Research
– Building a Biotech Company
– Interdisciplinary Collaboration in Biotech
– Tech and Biotech: Learning from Each Other
– Conclusion
0:00
48:13
Download MP3
Show notes
Bringing new drugs to market is a costly, time-consuming endeavor. On top of that, most medicines fail at some point in the research and development phase. Sarah Guo is joined by Sajith Wickramasekara, co-founder and CEO of Benchling, a company that has not only become the central system of record for biotech R&D, but uses AI agents to assist scientists to help fix this broken system. Sajith details the roadblocks that impede drug development and approval, the “dot com” bust occurring in biotech, and how AI agents and simulation can help scientists experiment faster. Plus, they talk about China’s competitive rise in the pharma space, and the unique challenges of building an interdisciplinary culture that merges the worlds of science and software. 
Rebuild biotech for the AI era - Sajith Wickramasekara
Sign up for new podcasts every week. Email feedback to [email protected]
Follow us on Twitter: @NoPriorsPod | @Saranormous | @EladGil | @sajithw | @benchling
Chapters: